disulfiram / Generic mfg. - LARVOL DELTA

Burden of Alcoholic Liver Disease and Underutilization of FDA-Approved Medication for Alcohol Use Disorder: A Real-World Analysis (ACG 2026) - "Among patients with ALD, we assessed the incidence and prevalence of patient treated with MAUD, including naltrexone, acamprosate, and disulfiram...Off-label agents such as baclofen (7.2%) and topiramate (3.2%) were prescribed at rates exceeding disulfiram (1.2%)... We identified 2.639.758 patients with AUD. ALD incidence rose from 779 to 2,911 per 100,000 in females and 1,320 to 3,702 in males, while prevalence reached 7,484 in females and 9,288 in males by 2025. MAUD incidence among ALD patients was higher in females than males."

Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • Hepatology • Substance Abuse

Glutathione-Responsive Disulfiram Delivery from Thiol-Functionalized N-Doped Carbon Nanodots: An in vitro Proof-of-Concept Study. (PubMed, Int J Nanomedicine) - "SNCDs provide an effective GSH-responsive nanoplatform for DSF delivery, combining high drug loading, excellent stability under non-reducing conditions, and efficient intracellular drug release under reductive environments. This strategy minimizes premature drug leakage while enhancing anticancer activity, demonstrating strong potential for cancer therapy."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

A phase 1/2 study of disulfiram and copper with concurrent radiation therapy and temozolomide for patients with newly diagnosed glioblastoma. (PubMed, Int J Radiat Oncol Biol Phys) - "The maximum tolerated dose of DSF with RT and TMZ is 375 mg/day. DSF/Cu showed limited clinical efficacy for most patients. However, promising efficacy was observed in BRAF-mutant GBM, warranting further investigation."

Journal • P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • BRAF • NF1

Disulfiram-Based Treatment for Scabies: Anti-Inflammatory and Antibacterial Benefits in Topical Combination Therapy (EADV 2026) - No abstract available

Combination therapy • Infectious Disease

Efficacy of Benzyl Benzoate and Disulfiram Emulsion Versus Permethrin Against Macrocyclic Lactone-Resistant Scabies Mites in an Ex Vivo Bioassay (EADV 2026) - No abstract available

Preclinical • Infectious Disease

Investigating disulfiram as a dual-action therapy for Pseudomonas aeruginosa infection in bronchiectasis (ERS 2026) - "There was a trend towards decreased unstimulated (vehicle=8903±2753 AU, disulfiram=3936±2752 AU, p=0.38, n=3) and LPS (vehicle=12522±4341 AU, disulfiram=6638±2742 AU, p=0.38, n=3) NET release at 1000ng/mL, and CD11b expression (vehicle=2269±981 AU, disulfiram=1984±926 AU, p=0.63) at 100ng/ml. Overall, disulfiram demonstrated no significant antibacterial or immunomodulatory effects against P. aeruginosa infection in bronchiectasis at concentrations tested."

Bronchiectasis • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • ITGAM

Inhibition of the xCT-GSH-GPX4 Axis Synergistically Enhances Disulfiram/Copper-Induced Cuproptosis in Non-Small Cell Lung Cancer (ERS 2026) - "Targeting the xCT-GSH-GPX4 axis synergistically enhances DSF/Cu-induced cuproptosis. The DSF/Cu plus curcumin combination is a novel, mechanistically grounded strategy for NSCLC. Keywords: NSCLC; Cuproptosis; Disulfiram; xCT-GSH-GPX4"

Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • DLAT • GPX4

SOGC Clinical Practice Guideline No. 471: Alcohol and Pregnancy. (PubMed, J Obstet Gynaecol Can) - "RECOMMENDATIONS: (Recommendations IN BOLD are new to this guideline update; an overview of the updated supporting literature for all recommendations is provided in Appendix B)."

Clinical guideline • Journal • Addiction (Opioid and Alcohol) • Obstetrics

Disulfiram Attenuates Adenine-Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses. (PubMed, FASEB J) - "Importantly, activation of gasdermin D, a central executor of pyroptosis, was closely associated with disease severity in human CKD biopsy samples, supporting the clinical relevance of this pathway. Collectively, these findings suggest a potential role for DSF in modulating inflammatory and immunometabolic pathways in CKD."

Journal • Addiction (Opioid and Alcohol) • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease

Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges. (PubMed, Int J Mol Sci) - "Consequently, current research focuses on advanced nanocarrier systems designed to protect DSF from premature degradation and ensure its controlled release within the tumor microenvironment. This review summarizes the multifaceted anticancer mechanisms of DSF and discusses biological and pharmacological factors underlying the discrepancies between experimental findings and clinical outcomes."

Journal • Review • Addiction (Opioid and Alcohol) • Oncology • Targeted Protein Degradation

Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation. (PubMed, Appl Microbiol Biotechnol) - "albicans. • Disulfiram competes with ATP for Cdr1 binding, disrupting fluconazole-Cdr1 interaction."

Journal • Infectious Disease • Oncology

ROS-Dependent GSDMD Activation Drives Intestinal Pyroptosis in Neonatal Necrotizing Enterocolitis (NEC). (PubMed, Cell Biol Int) - "Pharmacological inhibition of GSDMD (using disulfiram) similarly mitigated pyroptosis and enhanced the bactericidal capacity of macrophages. Further mechanistic studies indicated that ROS drive pyroptosis by activating GSDMD, and the antioxidant N-acetyl-l-cysteine (NAC) could reverse this effect. The findings suggest that GSDMD is a potential therapeutic target for NEC, and strategies targeting GSDMD inhibition (genetic or pharmacological), combined with antioxidant therapy, may offer novel treatment approaches for NEC."

Journal • Gastrointestinal Disorder • Inflammation • Inflammatory Bowel Disease • IL1B • NLRP3

Immune dysregulation in chronic diabetic wounds: therapeutic opportunities for healing reprogramming. (PubMed, Front Immunol) - "Emerging therapeutic strategies targeting the NLRP3 inflammasome pathway are reviewed, including pharmacological inhibitors (MCC950, glyburide, disulfiram), natural compounds (quercetin, resveratrol, tanshinone IIA), and advanced biomaterial-based approaches. The potential for macrophage phenotype reprogramming through metabolic intervention and the integration of inflammasome modulation with tissue engineering strategies are discussed. Understanding the intricate crosstalk between NLRP3 inflammasome activation and macrophage polarization provides a foundation for developing targeted therapies that can reprogram the diabetic wound microenvironment from a chronic inflammatory state toward effective healing resolution."

Journal • Review • Diabetes • Inflammation • Metabolic Disorders • IL18 • IL1B • NLRC5 • NLRP3

Can Psychedelics help with Alcohol Use Disorder (AUD): For now, the data says no. (PubMed, Sci Acad) - "On the contrary, current FDA-approved medications such as Naltrexone, Acamprosate, and Disulfiram are aimed at minimizing relapse, moderating craving, and promoting continued abstinence. Policy should focus primarily on integrating and improving patient access to existing multimodal approaches, such as pharmacotherapy in primary and telehealth care, and behavioral supports such as AA. While psychedelics do present an intriguing prospect, the priority should be implementing what works now while rigorously testing what may enhance care in the future."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry

Distinct Effects of Copper Ionophores on Intracellular Copper and Cell Viability in Wild-Type and CTR1-Deficient SH-SY5Y Cells. (PubMed, ACS Omega) - "In this study, we investigated the effects of selected copper-binding compoundsα-lipoic acid (LA), elesclomol (ES), disulfiram (DSF), thiourea (TU), and triapine (3-AP)on copper uptake and cytotoxicity in SH-SY5Y wild-type (WT) and CTR1-deficient (CTR1-/-) cells. Overall, our results demonstrate that copper ionophores can enhance intracellular copper levels dependently and independently of CTR1, with distinct effects on cell viability. Among the tested compounds, LA and DSF showed a favorable profile by increasing copper levels while maintaining low cytotoxicity, highlighting their potential for modulating cellular copper homeostasis."

Journal • Alzheimer's Disease • CNS Disorders

Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review. (PubMed, Pharmaceuticals (Basel)) - "The statistical ranking of the metformin-based combinations followed a descending order: disulfiram, diclofenac, nitroglycerin, itraconazole, and caffeine. By synthesizing previously fragmented primary data into a unified comparative framework, these findings provide a strong, consolidated preclinical rationale for metformin-based combination strategies. The established hierarchy of adjuvant potency resolves structural ambiguity and supports further translational and clinical investigation to evaluate their therapeutic potential in fibrosarcoma and other malignancies."

Journal • Review • Diabetes • Fibrosarcoma • Metabolic Disorders • Oncology • Sarcoma • Solid Tumor

Overcoming Resistance: Targeting Survivin-Driven Apoptotic Resistance Restores Irinotecan Sensitivity in TP53-Mutant Colorectal Cancer. (PubMed, Cancers (Basel)) - "This study aimed to determine whether targeting Survivin, a key inhibitor of apoptosis, and using the disulfiram-derived compound CuET could restore apoptotic signaling and improve irinotecan efficacy. Targeting this pathway, either directly through Survivin inhibition or through CuET-induced stress responses, restores apoptotic sensitivity and enhances chemotherapy efficacy. This study supports the development of combination strategies incorporating CuET to overcome resistance in TP53-mutant CRC."

Journal • Colorectal Cancer • Oncology • Solid Tumor • BIRC5 • TP53

From Neurobiological Mechanisms to Personalised Prescribing: A Prospective Three-Way Comparison of Anti-Craving Agents in ICD-11 Alcohol Dependence (WFSBP 2026) - "Objective: To compare 3-month relapse rates, craving reduction (OCDS), adherence, side effects, and dropout rates among patients with ICD-11 Alcohol Dependence (6C40) prescribed acamprosate, baclofen, or disulfiram in a real-world Indian clinical setting. First prospective three-way comparison in an Indian ICD-11 AUD population. Baclofen offers rapid craving control (titrate ≤60mg/day); disulfiram is effective only under supervision; acamprosate provides best real-world adherence. Personalised prescribing based on craving severity and social support improves AUD outcomes in Indian settings."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders

AI-augmented discovery of autophagy regulators through mechanistic interpretation of multiomics data. (PubMed, Autophagy) - "Furthermore, LyMOI revealed that two cancer-associated proteins, CTSL and FAM98A, are required for maintaining autophagy activity upon disulfiram (DSF) treatment...Notably, combination treatment with DSF and Z-FY-CHO, a CTSL-specific inhibitor previously developed against SARS-CoV-2 infection, potently suppressed tumor growth. Collectively, our work presents an LLM-powered platform with biologist-like reasoning for uncovering autophagy regulatory mechanisms."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Targeted therapy of colon cancer with aptamer-functionalized albumin nanoparticles loaded with disulfiram. (PubMed, Nanotechnology) - "To overcome these limitations, we developed a novel targeted drug delivery system (Apt-NPs-DSF) by encapsulating disulfiram (DSF) within albumin nanoparticles (NPs) functionalized with the nucleolin-targeting AS1411 aptamer. Importantly, in vivo study confirmed that Apt-NPs-DSF achieved superior antitumor efficacy without raising systemic toxicity, outperforming non-targeted counterparts. Collectively, these results suggest that Apt-NPs-DSF has potential in the targeted treatment of colon cancer."

Journal • Colon Cancer • Colorectal Cancer • Developmental Disorders • Oncology • Solid Tumor • NCL

Identifying candidate therapeutic targets in amyotrophic lateral sclerosis through a transcriptome-wide machine-learning consensus approach for drug repurposing. (PubMed, Neuroscience) - "Deferoxamine and disulfiram showed the clearest reversal-compatible profiles in motor cortex, whereas yohimbic acid and atovaquone showed reversal-compatible profiles in blood. Ciprofloxacin, prochlorperazine, and a compound group led by androsterone instead showed concordant connectivity. The results provide transparent, hypothesis-generating gene, pathway, and compound priorities, but they do not establish biomarkers, therapeutic efficacy, or clinical suitability and require validation in independent cohorts and experimental ALS models."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders

Podocyte-specific acid sphingomyelinase overexpression promotes gasdermin D dependent pyroptosis by impairing autophagic flux during obesity. (PubMed, Front Physiol) - "In contrast, inhibition of GSDMD pore formation with disulfiram (DIS) prevented HFD-induced pyroptosis without affecting NLRP3 inflammasome activation...Furthermore, PA-induced impairment of lysosome-autophagosome interaction and increased GSDMD pore formation were attenuated by the TRPML1 agonist ML-SA5 and exacerbated by the TRPML1 inhibitor ML-SI1. Collectively, these findings indicate that ASM regulates lysosomal function and autophagic degradation of GSDMD-NT, thereby controlling GSDMD pore formation and pyroptosis in podocytes during ORG."

Journal • Genetic Disorders • Glomerulonephritis • Obesity • NLRP3

The many faces of disulfiram-induced encephalopathy: diagnostic challenges in clinical practice. (PubMed, Acta Neurol Belg) - No abstract available

Journal • CNS Disorders

MicroRNA-223-3p/NLRP3 axis attenuates LPS-induced sepsis-like myocardial dysfunction by suppressing cardiomyocyte pyroptosis. (PubMed, Mol Biol Rep) - "These findings demonstrate that miR-223-3p attenuates LPS-Induced SLMD by inhibiting the NLRP3 inflammasome and cardiomyocyte pyroptosis."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Inflammation • Septic Shock • CASP1 • MIR223 • NLRP3

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma. (PubMed, Cancer Rep (Hoboken)) - "Repurposed drugs may provide useful candidates for improving TMZ-based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood-brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well-designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment."

Journal • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • AMPK • EGFR • MGMT • STAT3